FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

US FDA Commissioner notes that combined-phase clinical trials could be expanded beyond oncology as one way of reducing drug development costs.

FDA entrance sign 2016

US FDA Commissioner Scott Gottlieb touted the use of combined-phase studies, or "seamless trials," by oncology sponsors, indicating that the method could become more widely adopted beyond the field of cancer drug development.

More from Clinical Trials

Science and Politics May Collide As US FDA Offers More Precise Definitions Of Sex And Gender

 

The draft guidance clarifies that sex and gender are not interchangeable, but could be vulnerable in the Trump Administration as Republicans have argued against transgender medical care and that sex and gender must be congruent.

Off-Label Communications: US FDA Clarifies Safe Harbor For Firm-Generated Presentations

 
• By 

Final guidance on communicating scientific information on unapproved uses (SIUU) allows firm-generated presentations to be based on sources other than reprints, but says communications based on nonscientific content are not protected from enforcement.

Boosting Reliability: EMA Backs AI Tool For MASH Trials

 

An artificial intelligence-based pathology tool for metabolic dysfunction-associated steatohepatitis shows promise for a drug development landscape that is said to be “fraught with trials that have shown borderline results or outright failures based on liver histology.”

Protect Clinical Trial Data From The Start To Promote Privacy, Build Trust

 
• By 

Clinical trial sponsors should strive to strike a balance between privacy and transparency at the very beginning of a trial to be successful, advises Certara’s Honz Slipka.

More from R&D